Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of NS-304 (selexipag) in CTEPH
jRCT2080221625Phase 2
- Sponsor
- Nippon Shinyaku
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selexipag in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Nippon Shinyaku.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCT2080221625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221625.